Individualized Approach Helps When Intensifying GLP-1 Therapy in T2D

For patients with type 2 diabetes (T2D) who are not responding adequately to glucagon-like peptide-1 (GLP-1) therapy alone, a new guideline offers the clearest roadmap for pharmacists to make individualized treatment intensification decisions. According to Diabetes Research and Clinical Practice, careful and individualized decisions are key in addressing glycemic goals, hypoglycemia risk, weight considerations, treatment burden, and patient preferences.¹

“GLP-1 medications have changed the weight-loss landscape, but as their use expands, some people discover they fall into a less-discussed category: nonresponders,” wrote authors from Yale Medicine.² “The term refers to people who do not experience a meaningful benefit from a medication after an adequate dose and duration.”

The study shows that after 1 year of GLP-1 receptor agonist treatment, 60% to 70% of individuals with diabetes still fail to achieve optimal blood glucose control. Furthermore, high rates of therapy discontinuation complicate long-term management goals, with 50% to 75% of patients stopping their GLP-1 medications within a single year.^1,3

Sadiya Khan, MD, of Northwestern Medicine, noted that these high dropout rates should alarm clinicians and public health professionals, pointing to high medication costs and perceptions regarding long-term therapeutic necessity as driving factors. According to Yale Medicine specialists, impaired glucose regulation in patients with diabetes often leads to lower weight loss on GLP-1 medications compared with individuals without diabetes.^2,3

READ MORE: Diabetes Medications Adjustments for Older Adults Lower Than ADA Guidelines

What the Guideline Says About GLP-1 Intensification

To address suboptimal glycemic responses, the new Asia-Pacific guideline panel systematically evaluated 4 main injectable intensification strategies for patients who remain uncontrolled on GLP-1 monotherapy.¹

The guideline development group conditionally recommends against simply switching from one GLP-1 to another due to very low certainty evidence showing little to no consistent benefit in glycemic control or body weight. Instead, the panel highlights that introducing alternative glucose-lowering mechanisms yields far superior therapeutic outcomes, requiring pharmacists to evaluate distinct patient-specific priorities when selecting next-step options.

When evaluating intensification options, switching to a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist like tirzepatide demonstrated significant glycemic and weight-reduction benefits over remaining on GLP-1 monotherapy.¹

For patients who prioritize glycemic improvement above all, switching to a fixed-ratio combination of basal insulin and GLP-1 provided substantial reductions in glycated hemoglobin.

Alternatively, adding basal insulin to existing GLP-1 therapy also offers robust glucose-lowering effects, although both insulin-containing strategies carry a slight increase in hypoglycemia risk and require structured patient education and regular monitoring.¹

Practice Pillars for Optimizing Outcomes

Clinical pharmacists are uniquely positioned to navigate these complex therapeutic transitions through team-based collaborative drug therapy management agreements. Within primary care and specialty clinics, embedded pharmacists perform comprehensive patient assessments, adjust medication regimens, order necessary laboratory tests, and provide specialized counseling to accelerate metabolic goal attainment.^4,5

By conducting frequent follow-up visits and providing tailored self-management education, pharmacists effectively bridge gaps in primary care access and significantly improve long-term treatment adherence.⁴

To ensure successful treatment escalation, clinical pharmacists should operationalize practice pillars centered on education, medication access, and patient advocacy. They must deliver structured education regarding injection techniques, hypoglycemia management, and dietary adjustments to mitigate dose-dependent gastrointestinal side effects.^1,4,5

Additionally, pharmacists play a role in addressing financial and coverage barriers, navigating prior authorizations, assisting with savings opportunities, and advocating for broader insurance coverage to prevent premature treatment discontinuation.^3,5

By tailoring intensification strategies to each patient's clinical profile, pharmacists can maximize therapeutic efficacy while supporting long-term health outcomes.^1,5

“This guideline addresses a critical evidence gap by being the first to provide a framework for treatment intensification beyond GLP-1 monotherapy in T2D, supported by question-specific, certainty-rated recommendations,” concluded the authors of the current study.¹ “The ultimate decision requires a careful, individualized assessment of glycemic goals, hypoglycemia risk, weight considerations, treatment burden, and patient preferences, supported by adequate patient education and follow-up.”

READ MORE: Diabetes Resource Center

REFERENCES

1. Luo Y, Xia J, Yao X, et al. Guideline on treatment intensification with injectable therapies beyond GLP-1 RA based therapies in type 2 diabetes. Diabetes Res Clin Pract. 2026;239:113474. doi:10.1016/j.diabres.2026.113474

2. MacMillan C. Are you a GLP-1 nonresponder? Yale Medicine. June 12, 2026. Accessed September 9, 2026. https://www.yalemedicine.org/news/are-you-a-glp-1-nonresponder

3. Why do so many patients stop taking GLP-1 medications within a year? Northwestern Medicine ​Breakthroughs for Physicians. February 2025. Accessed September 9, 2026. https://breakthroughsforphysicians.nm.org/endocrinology-research-article-high-discontinuation-rates-for-glp-1-medications.html

4. Orabone AW, Do V, Cohen E. Pharmacist-managed diabetes programs: improving treatment adherence and patient outcomes. Diabetes Metab Syndr Obes. 2022 Jun 20;15:1911-1923. doi: 10.2147/DMSO.S342936

5. Lingow S, Carris N, Clements J, et al. The pharmacist’s role in the use of incretin‐based therapies for weight management: an opinion of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. JACCP. 2025;8(10):1078-1093. doi:10.1002/jac5.70111